Gabra1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Protein Name |
GABA-A Receptor Alpha1 Subunit |
| Gene |
GABRA1 |
| UniProt ID |
P14867 |
| PDB ID |
1DW6, 5OSM |
| Molecular Weight |
51 kDa |
| Subcellular Localization |
Plasma membrane (synaptic and extrasynaptic) |
| Protein Family |
Cys-loop ligand-gated ion channel receptor family |
The GABA-A receptor alpha1 subunit is a member of the Cys-loop ligand-gated ion channel family. Each subunit consists of:
- Extracellular N-terminal domain: Contains the characteristic Cys-loop motif and binding sites for GABA and benzodiazepines
- Transmembrane domains: Four hydrophobic helices (M1-M4) that form the ion channel pore
- Intracellular loop: Between M3 and M4, involved in trafficking and modulation
- C-terminal extracellular domain
The receptor is a heteromeric assembly of five subunits (typically 2α, 2β, 1γ or δ) forming a chloride channel.
- The alpha1 subunit is the most abundant GABA-A receptor subunit
- Forms receptors with distinct pharmacological properties
- Confers benzodiazepine sensitivity when combined with gamma2 subunit
- Mediates fast inhibitory synaptic transmission
- Regulates neuronal excitability throughout the CNS
- Controls sedation, anxiolysis, muscle relaxation, and anticonvulsant effects
- Important for sleep architecture
- GABRA1 mutations: Cause genetic epilepsy syndromes (JME,CAE,LGS)
- Mechanism: Loss-of-function mutations reduce inhibitory signaling
- Therapeutic target: Benzodiazepines enhance receptor function
- Alzheimer's Disease: Amyloid-beta affects GABA-A receptor function and localization
- Parkinson's Disease: Altered inhibitory signaling in basal ganglia circuits
- ALS: Changes in cortical inhibitory networks
| Drug |
Type |
Clinical Use |
| Diazepam |
Positive allosteric modulator |
Anxiety, sedation, anticonvulsant |
| Lorazepam |
Positive allosteric modulator |
Sedation, anticonvulsant |
| Zolpidem |
Selective agonist |
Insomnia |
| Phenobarbital |
Allosteric modulator |
Anticonvulsant |
| Drug |
Type |
Clinical Use |
| Flumazenil |
Competitive antagonist |
Benzodiazepine reversal |
- Sigel E, et al. (2012). GABA(A) receptor structure. J Neurochem. PMID:22243424
- Rudolph U, et al. (2001). GABA(A) receptor subtypes. Curr Pharm Des. PMID:11591105
The study of Gabra1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Sigel E, et al. (2012). Structure, function and modulation of GABA(A) receptors. J Neurochem. 122(1):54-67.
- Rudolph U, et al. (2001). GABA(A) receptor subtypes: novel drug discovery opportunities. Curr Pharm Des. 7(14):1399-1414.
- Möhler H. (2006). GABA(A) receptors in central nervous system disease. NeuroRx. 3(2):154-164.
- Macdonald RL, et al. (2010). GABA receptor mutations and epilepsy. Adv Exp Med Biol. 680:85-94.
- Sieghart W. (2006). Structure, pharmacology and function of GABA(A) receptor subtypes. Pharmacol Rev. 58(4):627-672.
- Whiting PJ. (2003). GABA-A receptor subtypes: function and pharmacology. Curr Opin Pharmacol. 3(1):101-106.
- Korpi ER, et al. (2002). GABA(A) receptor subunits: beyond the alpha/beta/gamma nomenclature. Trends Neurosci. 25(5):250-254.
- Luscher B, et al. (2011). GABA(A) receptor structure and function in the basal ganglia. Prog Brain Res. 187:59-76.